Next Article in Journal
Prophylactic Therapy with Human Amniotic Fluid Stem Cells Improves Long-Term Cognitive Impairment in Rat Neonatal Sepsis Survivors
Previous Article in Journal
Overexpression of Soybean-Derived Lunasin in Wheat and Assessment of Its Anti-Proliferative Activity in Colorectal Cancer HT-29 Cells
Open AccessArticle

BET-Inhibitor I-BET762 and PARP-Inhibitor Talazoparib Synergy in Small Cell Lung Cancer Cells

1
Department of Biomedical Science, and National Institute of Biostructures and Biosystems, University of Sassari, 07100 Sassari, Italy
2
Kitos Biotech Srls, Porto Conte Ricerche, 07041 Alghero, Italy
3
Sciomics GmbH, 69151 Neckargemünd, Germany
4
Division of Genome Biology, National Cancer Center Research Institute, Chuo-ku, Tokyo 104-0045, Japan
5
Center for Biotechnology, Department of Biology, Sbarro Institute for Cancer Research and Molecular Medicine, College of Science and Technology, Temple University, Philadelphia, PA 19122, USA
*
Author to whom correspondence should be addressed.
These authors contributed equally.
Int. J. Mol. Sci. 2020, 21(24), 9595; https://doi.org/10.3390/ijms21249595
Received: 11 November 2020 / Revised: 7 December 2020 / Accepted: 14 December 2020 / Published: 16 December 2020
(This article belongs to the Section Molecular Role of Xenobiotics)
Small cell lung cancer (SCLC) is an aggressive type of lung cancer with high mortality that is caused by frequent relapses and acquired resistance. Despite that several target-based approaches with potential therapeutic impact on SCLC have been identified, numerous targeted drugs have not been successful in providing improvements in cancer patients when used as single agents. A combination of targeted therapies could be a strategy to induce maximum lethal effects on cancer cells. As a starting point in the development of new drug combination strategies for the treatment of SCLC, we performed a mid-throughput screening assay by treating a panel of SCLC cell lines with BETi or AKi in combination with PARPi or EZH2i. We observed drug synergy between I-BET762 and Talazoparib, BETi and PARPi, respectively, in SCLC cells. Combinatorial efficacy was observed in MYCs-amplified and MYCs-wt SCLC cells over SCLC cells with impaired MYC signaling pathway or non-tumor cells. We indicate that drug synergy between I-BET762 and Talazoparib is associated with the attenuation HR-DSBR process and the downregulation of various players of DNA damage response by BET inhibition, such as CHEK2, PTEN, NBN, and FANCC. Our results provide a rationale for the development of new combinatorial strategies for the treatment of SCLC. View Full-Text
Keywords: SCLC; BET; PARP; BMN673; GSK-525762A SCLC; BET; PARP; BMN673; GSK-525762A
Show Figures

Figure 1

MDPI and ACS Style

Fiorentino, F.P.; Marchesi, I.; Schröder, C.; Schmidt, R.; Yokota, J.; Bagella, L. BET-Inhibitor I-BET762 and PARP-Inhibitor Talazoparib Synergy in Small Cell Lung Cancer Cells. Int. J. Mol. Sci. 2020, 21, 9595. https://doi.org/10.3390/ijms21249595

AMA Style

Fiorentino FP, Marchesi I, Schröder C, Schmidt R, Yokota J, Bagella L. BET-Inhibitor I-BET762 and PARP-Inhibitor Talazoparib Synergy in Small Cell Lung Cancer Cells. International Journal of Molecular Sciences. 2020; 21(24):9595. https://doi.org/10.3390/ijms21249595

Chicago/Turabian Style

Fiorentino, Francesco P.; Marchesi, Irene; Schröder, Christoph; Schmidt, Ronny; Yokota, Jun; Bagella, Luigi. 2020. "BET-Inhibitor I-BET762 and PARP-Inhibitor Talazoparib Synergy in Small Cell Lung Cancer Cells" Int. J. Mol. Sci. 21, no. 24: 9595. https://doi.org/10.3390/ijms21249595

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop